RxDoctor Payments Data

Mehran Nowfar-Rad, MD

Dermatopathology · Porter Ranch, CANPI 1912979048

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $832 and has fallen 83.1% since, to $141 in 2025.

$1,629in general payments, 2019–2025

Across 61 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$314
  • Amgen$274
  • Lilly USA, LLC$236
  • AbbVie$162
  • Dermavant Sciences, Inc.$79
  • Pfizer$79
  • plus $484 from 15 others

What the payments were for

  • Food & beverage$1,629100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,629 in reported general payments places this provider in the 70th percentile of 76 dermatopathology providers in California.

See all dermatopathology providers in California

Medicare billing

Part B allowed, 2024
$7,284
Medicare patients
24
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluocinonide61$1,555
Clobetasol Propionate29$646
Ketoconazole53$628
Metronidazole13$398
Clindamycin Phosphate25$351
Mupirocin37$291
Doxycycline Hyclate22$255
Hydroxyzine Hcl19$130
Triamcinolone Acetonide16$45
Hydrocortisone16$34

Paid to pharmacies, not to this prescriber.

Other dermatopathology in Porter Ranch

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →